Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000769189
Ethics application status
Approved
Date submitted
17/05/2019
Date registered
23/05/2019
Date last updated
3/05/2021
Date data sharing statement initially provided
23/05/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot study to evaluate the safety and efficacy of a personalised cancer vaccine in patients with completely resected early stage lung cancer
Scientific title
A pilot study to evaluate the safety and immunogenicity of a personalised tumour neo-antigen peptide vaccine strategy in patients with completely resected non-small cell lung cancer.
Secondary ID [1] 298271 0
None
Universal Trial Number (UTN)
Trial acronym
ATTAC (Antigen-targeted therapy against cancer)
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Lung Cancer 312883 0
Condition category
Condition code
Cancer 311377 311377 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Neoantigen peptide vaccine containing 5 - 10 peptides per vaccine depending on how many high affinity binding neo-antigens are predicted for each patient (ie some patients may only have 5 high affinity neo-antigens identified)
The vaccine will be administered 2 weekly for 4 doses then 4 weekly for 4 doses as a subcutaneous injection (fortnightly for the first 4 doses then 4 weekly for the next 4 doses)

Patients are provided with treatment schedule and will be reviewed by clinician prior to each dose for safety monitoring. CRFs will be completed for each visit.

Each dose will include 500mcg - 1000mcg of synthetic peptide (100mcg per peptide) in 0.5mL of Montanide as adjuvant by subcutaneous administration
Intervention code [1] 314515 0
Treatment: Drugs
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 320107 0
To evaluate the safety of the peptide vaccine strategy as assessed using CTCAE version 5.
Timepoint [1] 320107 0
From the time of the first dose of vaccination throughout the study follow-up period (52 weeks)
Secondary outcome [1] 370553 0
To evaluate the immunogenicity of the personalised tumour neo-antigen peptide vaccination by IFN-gamma ELISPOT analysis.
Timepoint [1] 370553 0
At baseline and weeks 5, 7, 11, 15, 19, 23, 35 and 52

Eligibility
Key inclusion criteria
1. Pathologically established diagnosis of NSCLC
2. Localised disease amenable to complete surgical resection
3. > 18 years of age
4. Eastern Cooperative Oncology Group (ECOG) performance status =1.
5. Life expectancy of >24 weeks
6. Patients who may require adjuvant chemotherapy are eligible
7. History of prior malignancy is eligible if the following criteria are met for a cancersurvivor:
7.1. has undergone potentially curative therapy for all prior malignancies,
7.2. has been considered disease free for at least 2 years
8. Women of reproductive potential must agree to use adequate contraception (two barrier methods or barrier method plus hormonal method of birth control; abstinence) prior to study entry and for the duration of study participation.
9. Males who are sexually active with women of reproductive potential must agree to use adequate contraception (two barrier methods or abstinence) prior to study entry and for the duration of study participation.
10. Able to provide written informed consent.
11. Must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.

Pre-Registration
12. Complete resection with margins negative for disease.
13. If required. Completed adjuvant platinum doublet chemotherapy as per standard oncological management
14. Adequate organ and marrow function no more than 14 days prior to registration as defined below:
Haemoglobin = 90g/L
WBC > 2 x 109/L
absolute neutrophil count > 1.5 x 109/L
platelets > 100 x 109/L
total bilirubin < 1.5 x ULN
ALT < 3.0 x ULN
creatinine < 1.5 x ULN
15. Adequate number of accessible tumour cells from resection.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Received chemotherapy, radiotherapy, or biologic therapy or other investigational therapeutic agent(s) within the last 21 days
2. Ongoing adverse effects from chemotherapy that have not resolved to = grade 1 (except haemoglobin= 90g/L is allowed)
3. Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, urticaria, or respiratory difficulty.
4. Uncontrolled significant intercurrent illness of major organ systems, or has psychiatric illness/social situation that would limit compliance with study requirements.
5. Prior or currently active significant autoimmune disease. Subjects with Type I diabetes mellitus, hypothyroidism requiring only hormone replacement are permitted to enroll.
6. Subjects with a condition requiring systemic corticosteroids or other immunosuppressive medications within 14 days of study treatment. Inhaled steroids and adrenal replacement steroids are permitted in the absence of active autoimmune disease.
7. Pregnant or breastfeeding. A negative serum pregnancy test is required in women of childbearing
potential no more than 7 days before registration.
8. Known HIV-positive status.
9. Any positive test result for Hepatitis B virus or hepatitis C virus indicating the presence of virus, e.g. Hepatitis B surface antigen (HBsAg) positive, or Hepatitis C antibody (anti-HCV) positive (except if HCV-RNA negative).
10. Known medical condition that, in the investigator’s opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
11. Subjects in whom the ability to observe possible local reactions at the eligible injection sites is, in the
opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art.
12. Therapeutic or traumatic metal implant in the skin or muscle of eligible injection sites.
13. Prisoners or subjects who are involuntarily incarcerated.
14. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/10/2020
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
6
Accrual to date
0
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 302814 0
Government body
Name [1] 302814 0
NHMRC
Country [1] 302814 0
Australia
Primary sponsor type
University
Name
University of Western Australia
Address
35 Stirling Hwy, Crawley WA 6009
Country
Australia
Secondary sponsor category [1] 302765 0
None
Name [1] 302765 0
Address [1] 302765 0
Country [1] 302765 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 303397 0
Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee
Ethics committee address [1] 303397 0
Ethics committee country [1] 303397 0
Australia
Date submitted for ethics approval [1] 303397 0
02/01/2018
Approval date [1] 303397 0
21/02/2018
Ethics approval number [1] 303397 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 93534 0
Prof Bruce Robinson
Address 93534 0
UWA School of Medicine and Pharmacology,
Level 5, Harry Perkins Research Building,
QEII Medical Centre, Nedlands, Perth, WA, 6009
Country 93534 0
Australia
Phone 93534 0
+61 8 6151 0923
Fax 93534 0
Email 93534 0
bruce.robinson@uwa.edu.au
Contact person for public queries
Name 93535 0
Linda Ye
Address 93535 0
Department of Medical Oncology
Sir Charles Gairdner Hospital
Hospital Ave Nedlands, WA, 6009
Country 93535 0
Australia
Phone 93535 0
+61 8 6457 3333
Fax 93535 0
Email 93535 0
yang.ye@health.wa.gov.au
Contact person for scientific queries
Name 93536 0
Linda Ye
Address 93536 0
Department of Medical Oncology
Sir Charles Gairdner Hospital
Hospital Ave Nedlands, WA, 6009
Country 93536 0
Australia
Phone 93536 0
+61 8 6457 3333
Fax 93536 0
Email 93536 0
yang.ye@health.wa.gov.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIDevelopment of tumour peptide vaccines: From universalization to personalization2020https://doi.org/10.1111/sji.12875
EmbaseThe Current Lung Cancer Neoantigen Landscape and Implications for Therapy.2021https://dx.doi.org/10.1016/j.jtho.2021.01.1624
N.B. These documents automatically identified may not have been verified by the study sponsor.